Stocks

JPMorgan Chase Lowers Price Target for BridgeBio Oncology to $23.00

Guavy AI Editorial Team Published September 11, 2026

Instruments

JPM

Analysts at JPMorgan Chase & Co. have lowered their price target for BridgeBio Oncology Therapeutics (NASDAQ:BBOT) from $25.00 to $23.00 in a recent research report.

This move comes after the brokerage maintained its 'overweight' rating on the stock, indicating potential growth opportunities.

The new price target suggests an upside of 361.38% from BridgeBio Oncology Therapeutics' current market value of $4.99 per share.

Chewy Stock Downgraded by JPMorgan Chase

Stocks 2m ago

SanDisk's 2,107% Surge Upends Value Indexes

Stocks 2m ago

SanDisk's 2,107% Surge Redefines Value Investing

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

Terms Privacy Policy